For pancreascancer konkluderede udvalget, at læger og patienter skulle tage patientens overlevelseschancer i betragtning, ved ordinering af Tarceva.
For pancreatic cancer, the committee concluded that doctors and patients should take the patient ’ s chances of survival into account when prescribing Tarceva.